Figure 4.

A, B, Autoradiographic analyses of dopamine transporter (A) and PBR (B) in striatal regions of mice without treatment and 2 and 7 d after initiation of METH treatment (n = 6 per group). Significant decline of [¹¹C]PE2I binding to dopamine transporter was observed after METH administration (**p < 0.01 by Bonferroni's multiple comparison after ANOVA), whereas changes in binding of [¹⁸F]FE-DAA1106 to PBR were insignificant (p > 0.05 by ANOVA). Error bars represent SE. Representative autoradiograms are displayed on top. C–H, Double immunofluorescence staining with anti-GFAP antibody (C–E) and NP155 (F–H) in striatal sections of mice without treatment (left) and 2 (middle) and 7 (right) d of METH challenge. I–L, Double immunofluorescence staining with anti-GFAP antibody (I, J) and NP155 (K, L) in contralateral (left column) and ipsilateral (middle column) striata of 6-OHDA-treated rats. Error bars in graphs represent SE. Scale bars, (C–L) 75 μm.